Eli Lilly Earnings Call Recap: Q1 2026

We just got done listening to the quarter one, 2026 Eli Lilly earnings call. There was a lot of information to get into, whether you're interested in retatrutide, eloralintide, or Foundayo, and all of the numbers that were so incredible to hear. This video analyzes Eli Lilly's Q1 2026 earnings call, discussing key products like eloralintide, brenipatide, and retatrutide, providing essential finance news and stock market news for those tracking pharmaceutical companies. The presenter highlights the strong start of Foundayo's U.S. launch and reviews the Lilly Select Pipeline, touching upon the U.S. Incretin Analogs Market and broader healthcare industry trends.

WAYS TO SUPPORT MY WORK ⬇️http://www.otplinks.com💊 OVER THE COUNTER ORAL PEPTIDE SUPPLIMENTS: BPC-157 // Can’t Weight // TB4-FRAG // KPVSign up here and use code “OTP10” to save 10%https://integrativepeptides.com/OTPWHY I TRUST INTEGRATIVE PEPTIDES:🇺🇸 Made in the USA📋 CGMP Compliant (FDA oversight of their products)🧑‍⚕️Trusted and Sold By Doctors and Clinics all over the USA📕 GET MY BOOK! Decoding GLP-1: A Guide for Friends and Family of Those On The Pen By Dave Knapphttps://amzn.to/4gAXrz4

Tämä jakso on lisätty Podme-palveluun avoimen RSS-syötteen kautta eikä se ole Podmen omaa tuotantoa. Siksi jakso saattaa sisältää mainontaa.

Jaksot(193)

Eli Lilly Isn’t Telling Us About Their Future Obesity Drugs

Does Eli Lilly already have the solve for obesity? In this episode of On the Pen — the Weekly Dose Podcast, host Dave Knapp breaks down a stunning comment from Lilly's Chief Scientific Officer Daniel ...

2 Kesä 20min

Retatrutide, Multi Agonist Obesity Drugs, and the PBM Access War

https://linktr.ee/manonthemounjaro

26 Touko 30min

Lilly Bets $8B on Weight Loss Future

https://linktr.ee/manonthemounjaro

19 Touko 23min

The Next Two Weeks in GLP1 Are Huge, Here's Why

http://www.otplinks.com

12 Touko 1h 7min

He Took Retatrutide 40mg and Proved a Point

This episode examines a serious case involving retatrutide, where an individual experienced an overdose due to improper medication administration. We discuss the critical importance of medication safe...

5 Touko 36min

SURVODUTIDE Phase 3 Data: Why Weight Loss Isn't The Whole Story

https://www.otplinks.comA new GLP-1 and glucagon agonist dropped data that was supposed to rival retatrutide, just without the GIP, and on the surface the results look solid. But that is not the real ...

28 Huhti 18min

BPI STOPS TIRZEPATIDE Production, Second Major Pharmacy Out!

Major disruption hits the GLP-1 landscape as another large 503B compounding pharmacy halts production of semaglutide and tirzepatide. In this episode, we unpack what’s driving the FDA’s increased enfo...

23 Huhti 40min